Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Commonly reported side effects include: Injection site reactions: Redness, irritation, or swelling at the injection site is the most frequent issue
Side Effects & Safety Typical first-cycle side effects: Weeks 1-2: mild water retention, vivid dreams, light head/warmth after injection Weeks 3-4: occasional joint stiffness, improved sleep quality, slight appetite increase overnight Weeks 5-8: adaptation phase most side effects fade, body composition changes visible Clinical discontinuation signals (trial-reported): Clinical participants in tesamorelin studies were discontinued upon experiencing: Persistent headaches with visual changes (intracranial pressure marker in trial monitoring protocols) Sustained fasting glucose elevation of ~15 mg/dL above baseline Unusual peripheral swelling persisting beyond weeks 1-2 Carpal tunnel symptoms unresponsive to dose titration in community-reported protocols Tesamorelin has been studied at 2mg/day for 6+ months without notable safety signals at therapeutic doses
Upon binding, GHRP-6 activates Gq/11 protein coupling, which stimulates phospholipase C (PLC) activity
Final Verdict The evidence is clear: there is no strong scientific data linking sermorelin to cancer development
